​

Processa Pharmaceuticals (PCSA) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

PCSA Stock Forecast

Processa Pharmaceuticals (PCSA) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $225.00, with a high of $225.00 and a low of $225.00. This represents a 8390.57% increase from the last price of $2.65.

- $50 $100 $150 $200 $250 High: $225 Avg: $225 Low: $225 Last Closed Price: $2.65

PCSA Stock Rating

Processa Pharmaceuticals stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (80.00%), 1 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 4 Strong Sell Sell Hold Buy Strong Buy

PCSA Price Target Upside V Benchmarks

TypeNameUpside
StockProcessa Pharmaceuticals8390.57%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$2.65$2.65$2.65
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 26-1---1
Mar, 26-1---1
Feb, 26-11--2
Jan, 26-11--2
Dec, 25-11--2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 19, 2022Maxim Group$9.00$3.18183.02%239.62%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 02, 2025H.C. WainwrightBuyBuyhold
Oct 03, 2024H.C. WainwrightBuyBuyhold
Jan 12, 2023Maxim GroupBuyBuyhold
Aug 03, 2021OppenheimerOutperforminitialise

Financial Forecast

EPS Forecast

$-250 $-200 $-150 $-100 $-50 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-212.00$-96.75---
Avg Forecast$-8.80$-4.05$-2.16$-6.20$-5.40
High Forecast$-8.49$-4.05$-2.16$-6.20$-5.40
Low Forecast$-9.11$-4.05$-2.16$-6.20$-5.40
Surprise %2309.09%2288.89%---

Revenue Forecast

$10M $11M $12M $13M $14M $15M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported-----
Avg Forecast--$14.91M$10.01M$10.36M
High Forecast--$14.91M$10.01M$10.36M
Low Forecast--$14.91M$10.01M$10.36M
Surprise %-----

Net Income Forecast

$-15M $-12M $-9M $-6M $-3M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-11.12M$-11.85M$-13.56M--
Avg Forecast$-11.54M$-5.31M$-2.83M$-8.13M$-7.08M
High Forecast$-11.13M$-5.31M$-2.83M$-8.13M$-7.08M
Low Forecast$-11.95M$-5.31M$-2.83M$-8.13M$-7.08M
Surprise %-3.64%123.09%378.78%--

PCSA Forecast FAQ

Is Processa Pharmaceuticals stock a buy?

Processa Pharmaceuticals stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Processa Pharmaceuticals is a favorable investment for most analysts.

What is Processa Pharmaceuticals's price target?

Processa Pharmaceuticals's price target, set by 5 Wall Street analysts, averages $225 over the next 12 months. The price target range spans from $225 at the low end to $225 at the high end, suggesting a potential 8390.57% change from the previous closing price of $2.65.

How does Processa Pharmaceuticals stock forecast compare to its benchmarks?

Processa Pharmaceuticals's stock forecast shows a 8390.57% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Processa Pharmaceuticals over the past three months?

  • April 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.

What is Processa Pharmaceuticals’s EPS forecast?

Processa Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-6.2, marking a 0% decrease from the reported $0 in 2025. Estimates for the following years are.

What is Processa Pharmaceuticals’s revenue forecast?

Processa Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $10.01M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for.

What is Processa Pharmaceuticals’s net income forecast?

Processa Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-8.132M, representing a -40.05% decrease from the reported $-13.564M in 2025. Projections indicate .